WO2023239573A1 - Traitement d'alliages cobalt-tungstène - Google Patents

Traitement d'alliages cobalt-tungstène Download PDF

Info

Publication number
WO2023239573A1
WO2023239573A1 PCT/US2023/023963 US2023023963W WO2023239573A1 WO 2023239573 A1 WO2023239573 A1 WO 2023239573A1 US 2023023963 W US2023023963 W US 2023023963W WO 2023239573 A1 WO2023239573 A1 WO 2023239573A1
Authority
WO
WIPO (PCT)
Prior art keywords
alloy
stent
cobalt
tungsten
platinum
Prior art date
Application number
PCT/US2023/023963
Other languages
English (en)
Inventor
Donal F. MANLEY
Puneet Kamal Singh Gill
Diarmuid P. MEAGHER
Original Assignee
Abbott Cardiovascular Systems, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US18/324,749 external-priority patent/US20230399725A1/en
Application filed by Abbott Cardiovascular Systems, Inc. filed Critical Abbott Cardiovascular Systems, Inc.
Publication of WO2023239573A1 publication Critical patent/WO2023239573A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22C—ALLOYS
    • C22C30/00—Alloys containing less than 50% by weight of each constituent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02—Inorganic materials
    • A61L31/022—Metals or alloys
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22C—ALLOYS
    • C22C19/00—Alloys based on nickel or cobalt
    • C22C19/07—Alloys based on nickel or cobalt based on cobalt
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22F—CHANGING THE PHYSICAL STRUCTURE OF NON-FERROUS METALS AND NON-FERROUS ALLOYS
    • C22F1/00—Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
    • C22F1/002—Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working by rapid cooling or quenching; cooling agents used therefor
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22C—ALLOYS
    • C22C27/00—Alloys based on rhenium or a refractory metal not mentioned in groups C22C14/00 or C22C16/00
    • C22C27/06—Alloys based on chromium
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22C—ALLOYS
    • C22C5/00—Alloys based on noble metals
    • C22C5/04—Alloys based on a platinum group metal

Definitions

  • Intraluminal stents implanted with percutaneous methods have become a standard adjunct to procedures such as balloon angioplasty in the treatment of atherosclerotic disease of the arterial system. Stents, by preventing acute vessel recoil, improve long-term patient outcome and have other benefits such as securing vessel dissections.
  • Intraluminal stents comprise generally tubular-shaped devices that are constructed to hold open a segment of a blood vessel or other anatomical lumen. Intraluminal stents are used in treatment of diseases such as atherosclerotic stenosis as well as diseases of the stomach and esophagus, and for urinary tract applications. Adequate stent function requires a precise placement of the stent over a lesion or site of plaque or other lumen site in need of treatment. Typically, the stent is delivered to a treatment site by a delivery catheter that comprises an expandable portion for expanding the stent within the lumen.
  • the delivery catheter onto which the stent is mounted may be a balloon delivery catheter similar to those used for balloon angioplasty procedures.
  • the stent may be compressed onto the balloon.
  • the catheter and stent assembly is introduced within a patient's vasculature using a guide wire.
  • the guide wire is disposed across the damaged arterial section and then the catheter- stent assembly is advanced over the guide wire within the artery until the stent is directly within the lesion or the damaged section.
  • the balloon of the catheter is expanded, expanding the stent against the artery wall.
  • the artery is preferably slightly expanded by the expansion of the stent to seat or otherwise fix the stent to prevent movement.
  • the artery may have to be expanded considerably in order to facilitate passage of blood or other fluid therethrough.
  • the stent is expanded by retraction of a sheath or actuation of a release mechanism.
  • Self-expanding stents may expand to the vessel wall automatically without the aid of a dilation balloon, although such a dilation balloon may be used for another purpose.
  • the stent radiopacity arises from a combination of stent material and stent pattern, including stent strut or wall thickness. After deployment within the vessel, the stent radiopacity should allow adequate visibility of both the stent and the underlying vessel and/or lesion morphology under fluoroscopic visualization.
  • Stent radiopacity relies on the use of materials having high density, a high atomic number and/or a high electron density contrast compared to the stent’s surroundings.
  • alloy materials are available, there remains a need for improved alloy materials, exhibiting enhanced properties, as well as methods for processing such alloys, e.g., to ensure they exhibit fine grain structure and/or minimal inclusions.
  • the present disclosure thus relates to processing methods that can be used to substantially eliminate the occurrence of such a secondary phase from a cobalt-chromium alloy that includes platinum or another radiopacifying metal, as described herein.
  • alloys including cobalt and chromium with platinum as a particularly contemplated radiopacifier benefit from the present processing methods, it will be appreciated that the present methods may also be applicable to other alloys, e.g., using additional or other high density, high atomic number radiopacifier metals, such as the various platinum group metals, precious metals, or refractory metals and the alloys thereof described in applicant’s U.S. Patent Nos. 9,566,147; 10,441,445, and Application Nos. 16/601,259; 17/068,526 and 17/562,592, each of which is herein incorporated by reference in its entirety.
  • One embodiment of the present disclosure includes a process for producing a substantially homogenous cobalt-chromium alloy including tungsten and at least one of a platinum group metal, a precious metal, refractory metal, or other radiopacifying element having an atomic number and/or density greater than that of cobalt.
  • Such a process may include providing an alloy formed from cobalt, chromium, tungsten, and at least one of a platinum group metal, precious metal, refractory metal, or other radiopacifying element having an atomic number and/or density greater than that of cobalt and heating the alloy to a temperature of about 1250°C for a time period of about 30 minutes, and rapidly quenching the alloy to 600°C or less within about 5 minutes (e.g., within 1 minute or less).
  • longer treatment times e.g., 60 minutes at 1250°C
  • higher temperatures e.g., 1275°C for 60 minutes
  • Another exemplary process for producing a substantially homogenous cobaltchromium alloy including cobalt, chromium, tungsten and platinum may include providing the alloy formed from cobalt, chromium, tungsten and platinum, wherein said alloy includes precipitate inclusions, so as to not be substantially homogenous.
  • the alloy having such precipitate inclusions is heated to a temperature from about 1225°C to 1275°C for a time period from about 20 minutes to 40 minutes to substantially remove the precipitate inclusions from the alloy, providing a substantially homogenous alloy, followed by rapidly quenching the alloy to 600°C or less within about 5 minutes (e.g., within 1 minute or less).
  • Another exemplary process for producing a stent formed from a substantially homogenous cobalt chromium alloy including cobalt, chromium, tungsten and platinum may include providing the alloy in the form of a tube or rod formed from cobalt, chromium, tungsten, and platinum, where said alloy includes precipitate inclusions so as to not be substantially homogenous, and heating the alloy to a temperature from about 1225°C to 1275°C for a time period from about 20 to 40 minutes to remove the precipitate inclusions from the alloy, providing a substantially homogenous alloy. After such heating, the alloy is rapidly quenched to 600°C or less within about 5 minutes (e.g., within 1 minute or less), and the tube or rod is drawn to form the desired stent.
  • the alloy comprises cobalt, chromium, tungsten, and platinum.
  • the alloy may not include any other elements in amounts greater than about 10% by weight.
  • the alloy may include nickel in an amount of about 10% by weight, with no other elements present in higher amounts.
  • any additional elements may be present in amounts no greater than 5%, no greater than 3%, no greater than 2%, or no greater than 1% by weight.
  • rapid quenching may be performed within a time period of less than 5 minutes, less than 3 minutes, less than 2 minutes, or less than 1 minute.
  • the rapid quenching may be performed with water (e.g., by immersing the alloy in water).
  • the alloy may include cobalt in an amount from about 20% to 40% by weight.
  • the alloy may include chromium in an amount of about 20% by weight.
  • the alloy may include nickel in an amount of about 10% by weight.
  • the alloy may be substantially or entirely free of molybdenum (and/or other elements of the periodic table not mentioned herein).
  • the alloy may be substantially or entirely free of carbon.
  • the alloy may include no more than 1%, no more than 0.5%, no more than 0.1%, or no more than 0.05% by weight of one or more of silicon, phosphorus, or sulfur.
  • the alloy may further include manganese in an amount of up to 5%, up to 3%, or up to 2% (e.g., 1-2%) by weight.
  • the alloy may further include iron in an amount of up to 5%, up to 3%, or up to 2% (e.g., 0-3%) by weight.
  • the alloy may further include both manganese and iron in an amount of up to about 3% each, by weight.
  • the sum of the percentage of cobalt and platinum in the alloy may be from 48% to about 60%, or 50% to 57% (e.g., about 55%).
  • the alloy may include: about 20-37% cobalt; about 20-30% platinum; about 19-21% chromium; about 14-16% tungsten; about 9-11% nickel; and about 1-2% manganese.
  • the alloy may include one or more trace elements as follows:
  • the precipitate inclusions may include tungsten (e.g., C03W).
  • the alloy may be used to form a radiopaque stent.
  • the radiopaque stent comprises a cylindrical main body, where the body is formed (e.g., entirely) from the substantially homogenous alloy as described herein.
  • the alloy may include chromium (e.g., in a concentration of about 20% by weight), and nickel in a concentration of 5-15% by weight (e.g., about 10% by weight), as well as small quantities of manganese (e.g., in a concentration of 0-5% by weight), iron (e.g., in a concentration of 0-5% by weight), as well as other trace elements as noted, e.g., in a concentration of 1% maximum, 0.5% maximum, 0.3% maximum, 0.2% maximum, 0.1% maximum, 0.05% maximum, or 0.01% maximum.
  • Exemplary trace elements may include silicon (e.g., up to about 0.04%), phosphorus (up to about 0.04%), and sulfur (up to about 0.03%).
  • Other trace elements typically present in an L-605 alloy e.g., beryllium, boron, carbon
  • substantially free as used herein may mean that if present, such a constituent is present in the alloy in an amount of less than 0.05%, less than 0.04%, less than 0.03%, less than 0.02%, less than 0.01%, less than 0.001%, or preferably 0% by weight.
  • the phrase “substantially homogenous” as used herein may mean that if any secondary phase precipitate phase is present, such is present in an amount of less than 2%, less than 1%, less than 0.5%, or less than 0.1% volume fraction of a secondary precipitate inclusion phase.
  • the particles of such a secondary precipitate inclusion phase may have a maximum or even average particle size of less than 5 pm, less than 4 pm, less than 3 pm, less than 2 pm, or less than 1 pm.
  • any such secondary precipitate inclusion phase is finely dispersed, e.g., with a maximum or average particle size that may be less than 10%, less than 5%, less than 3%, less than 2%, or less than 1% of the wall thickness of a stent wall (e.g., about 100 pm).
  • maximum or even average particle size of any finely dispersed secondary precipitate inclusion phase may be less than 10%, less than 5%, less than 3%, less than 2%, or less than 1% that of the wall thickness (e.g., 5 pm or less, 4 pm or less, 3 pm or less, 2 pm or less, or even 1 pm or less) so that the presence of any such precipitate inclusion has a minimal impact on desired mechanical properties.
  • the presence of such precipitate inclusions can be substantially eliminated by heating the solid alloy to about 1250°C, for about 30 minutes followed by rapid quenching.
  • FIG. 1 is an SEM image of an exemplary cobalt-chromium-tungsten alloy, taken during tube draw, showing the presence of undesirable precipitates in the alloy structure.
  • FIG. 2 is a time, temperature, transition (TTT) graph for L-605 cobaltchromium alloy.
  • FIG. 3 shows a binary phase diagram for cobalt-chromium.
  • FIG. 4 is an SEM image of a similar cobalt-chromium-tungsten alloy as shown in FIG. 1, before a heat treatment according to the present disclosure, showing undesirable precipitates.
  • FIG. 5 is an SEM image of the alloy of FIG. 4, after the heat treatment according to the present disclosure, where the undesirable precipitates have been substantially removed.
  • FIG. 6 is a perspective view of a tubular embodiment of a radiopaque stent of that can be formed according to the present invention.
  • FIG. 7 is a side view of a coiled configuration of a radiopaque stent that can be formed according to the present invention.
  • FIG. 8 is a perspective view of a ratcheted configuration of a radiopaque stent that can be formed according to the present invention.
  • FIG. 9 is a perspective view of a configuration of a radiopaque stent that includes a backbone that can be formed according to the present invention.
  • FIG. 10 is a perspective view of another configuration of a radiopaque stent that includes a staggered backbone that can be formed according to the present invention.
  • FIG. 11 is a perspective view of a configuration of a radiopaque stent that can be formed according to the present invention, in an unexpanded state, with one end of the stent being shown in an exploded view to illustrate the details thereof.
  • FIG. 12 is a plan view of a flattened section of a radiopaque stent configuration which can be formed according to the present invention, which illustrates an undulating pattern of the stent shown in FIG. 11.
  • FIG. 12a is a sectional view taken along the line 12a-12a in FIG. 12.
  • FIG. 13 is an elevational view, partially in section, of a radiopaque stent that can be formed according to the present invention, mounted on a delivery catheter and disposed within a damaged lumen.
  • FIG. 14 is an elevational view, partially in section, showing the radiopaque stent of FIG. 13 within a damaged lumen.
  • FIG. 15 is an elevational view, partially in section, showing the radiopaque stent of FIG. 13 expanded within the lumen after withdrawal of the delivery catheter.
  • FIG. 16 is a schematic representation of equipment for selectively cutting the tubing in the manufacture of the radiopaque stent of the present invention.
  • An embodiment of the present disclosure includes processes for processing alloys that include a significant fraction of a platinum group metal, refractory metal, or other precious or exotic metal having an atomic number and/or density greater than that of cobalt, as a radiopacifier, while minimizing or eliminating the occurrence of inclusions of a secondary phase throughout manufacturing, processing, and use.
  • the present disclosure relates to processing methods that can be used to substantially eliminate the occurrence of such a secondary phase from a cobaltchromium alloy that includes platinum or another such radiopacifying metal that significantly increases radiopacity.
  • radiopacifier metals such as the various platinum group metals, precious metals, or refractory metals and the alloys thereof described in applicant’s U.S. Patent Nos. 9,566,147; 10,441,445, and Application Nos. 16/601,259; 17/068,526 and 17/562,592, each of which is herein incorporated by reference in its entirety.
  • a wide variety of radiopacifier metals may be possible, including metals other than those described in the above referenced patents, so long as they are capable of forming a substantially homogenous single phase alloy, with increased radiopacity as compared to the cobalt being replaced.
  • An embodiment of the present disclosure includes a process for producing a substantially homogenous cobalt-chromium alloy including tungsten and at least one of a platinum group metal, a precious metal, refractory metal, or other selected metal as described herein to increase radiopacity.
  • Such a process may include providing an alloy formed from cobalt, chromium, tungsten, and at least one of a platinum group metal, precious metal, refractory metal or other metal selected to increase radiopacity, and heating the alloy to a temperature of about 1250°C for a time period of about 30 minutes, and rapidly quenching the alloy to 600°C or less within about 5 minutes.
  • Another exemplary process for producing a substantially homogenous cobaltchromium alloy including cobalt, chromium, tungsten and platinum may include providing the alloy formed from cobalt, chromium, tungsten and platinum, wherein said alloy can include precipitate inclusions, so as to not be substantially homogenous.
  • the alloy that may have such precipitate inclusions is heated to a temperature from about 1225°C to about 1275°C (preferably less than 1300°C to avoid incipient melting) for a time period from about 20 to 40 minutes to remove any precipitate inclusions from the alloy, providing a substantially homogenous alloy, and rapidly quenching the alloy to 600°C or less within about 5 minutes.
  • Another exemplary process for producing a stent formed from a substantially homogenous cobalt chromium alloy including cobalt, chromium, tungsten and platinum may include providing the alloy in the form of a tube or rod formed from cobalt, chromium, tungsten, and platinum, where said alloy may include precipitate inclusions so as to not be substantially homogenous, and heating the alloy to a temperature from about 1225°C to about 1275°C for a time period from about 20 to 40 minutes to remove any precipitate inclusions from the alloy, providing a substantially homogenous alloy. After such heating, the alloy is rapidly quenched to 600°C or less within about 5 minutes, and the tube or rod can be drawn to form the desired stent.
  • the radiopaque stent of the present disclosure comprises a main body, one embodiment of which is illustrated generally at 10 in FIG. 13, which can be fabricated from an alloy comprising cobalt-chromium-tungsten (Co-Cr-W), as well as an additional element providing radiopacity greater than that afforded by cobalt (e.g., addition of platinum).
  • the alloy may include at least 10%, at least 15%, or at least 20%, no more than 35%, or no more than 30%, such as from about 20% to about 30% by weight platinum.
  • Nickel may also be present (e.g., in an amount of from 5-15%, such as about 10%).
  • the alloy can be free or substantially free of precipitate inclusions present within the alloy structure.
  • the alloy can instead be in the form of a substantially single-phase microstructure, without (or substantially without) the presence of such precipitates or inclusions.
  • the substantial absence of such precipitates or inclusions also minimizes any tendency for microcracks or similar undesirable mechanical problems to occur.
  • the radiopaque Co-Cr-W alloy may be similar to L-605, but in which an amount of platinum is provided, e.g., reducing the amount of cobalt accordingly relative to L-605.
  • Such an alloy may be referred to by applicant as P-605.
  • the remaining weight fractions of other alloying elements in L-605 may remain unaltered (other than cobalt, which decreases).
  • alloy L-605 contains 14-16% by weight tungsten, 19- 21% by weight chromium, 9-11% by weight nickel, 1-2% manganese, with a balance (other than trace elements) being cobalt.
  • the cobalt may be present in an amount of from 20-40%, or 20-37%, where platinum is present at 20- 30% by weight.
  • the relative radiopacity of the resulting P-605 alloy is increased relative to L-605, and where care is taken during manufacture and processing of the alloy as described herein, the resulting alloy can advantageously have a substantially homogenous single-phase microstructure with little to no presence of precipitates or inclusions.
  • a substantially homogenous single-phase structure with minimal if any precipitates or inclusions can be achieved by using a very specific heat treatment regimen, where the alloy that includes (or may include) such precipitates or inclusions is heated to a temperature of from 1225°C to about 1275°C (e.g., about 1250°C) for a time period of from about 20 minutes to about 40 minutes to remove any precipitate inclusions that may be present within the alloy, followed by rapidly quenching the alloy to 600°C or less within about 5 minutes (e.g., typically within 1 minute).
  • a very specific heat treatment regimen where the alloy that includes (or may include) such precipitates or inclusions is heated to a temperature of from 1225°C to about 1275°C (e.g., about 1250°C) for a time period of from about 20 minutes to about 40 minutes to remove any precipitate inclusions that may be present within the alloy, followed by rapidly quenching the alloy to 600°C or less within about 5 minutes (e.g., typically within 1 minute).
  • the heat treatment is shorter than 60 minutes, such as no more than 50 minutes, or no more than about 40 minutes. In an embodiment, the heat treatment is at least 10 minutes, at least 15 minutes, or at least 20 minutes, such as about 30 minutes.
  • One particular combination of time and temperature that has been observed to work well is 30 minutes at 1250°C. Lower temperatures may be insufficient to dissolve precipitates that may be present, while slightly higher temperatures (e.g., greater than 1275°C, such as 1300°C) may be so high as to result in undesirable incipient melting.
  • Radiopaque Co-Cr-Ni-W-Pt alloy of the present disclosure is comprised of chromium in a concentration of about 20% (e.g., 15% to 25%) by weight, tungsten in a concentration that is about 15% (e.g., at least 10%, such as 10- 20% by weight, nickel in a concentration of 5-15% (e.g., about 10%) by weight, manganese in a concentration of 0-5% (e.g., 1-3%) by weight, and iron in a concentration of 0-5% (e.g., 0-3%, or 1-3%) by weight.
  • Trace elements may be present, if at all, in concentrations of less than 1%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, less than 0.1%, less than 0.05%, less than 0.04%, less than 0.03%, less than 0.02%, or less than 0.01% by weight.
  • Platinum or another metal selected to provide greater radiopacity than cobalt may be present in an amount of about 25%, such as from 15% to 40%, or 20% to 35%, or 20% to 30% by weight.
  • the balance of material may be cobalt, e.g., typically from about 20% to 40%, 20% to 35%, or 25% to 32% by weight.
  • the weight fractions for one or more of chromium, tungsten, manganese, iron, or nickel may be identical to those in L-605 (hence the applicant’s reference to the alloy as P-605).
  • the fractions of cobalt and platinum may be the only significant difference in composition relative to L-605, although the sum of the cobalt + platinum weight fractions may be equal to that of cobalt in L-605 (e.g., about 55%, such as 48-57%, or 50-57% by weight).
  • the alloy may be substantially or entirely free of molybdenum and/or carbon as deliberately added alloying elements. “Substantially free” as used herein may include less than 2%, less than 1.5%, less than 1%, less than 0.5%, less than 0.15%, less than 0.1%, less than 0.05%, less than 0.04%, less than 0.03%, less than 0.02%, or less than 0.01% weight.
  • an embodiment that is substantially free of carbon, but still includes a very small amount of carbon may include from 0.05% to 0.15% carbon.
  • the alloy may also be free or substantially free of any other elements of the periodic table not specifically noted as present.
  • the alloy comprises no more than 1%, no more than 0.5%, no more than 0.4%, no more than 0.3%, no more than 0.2%, no more than 0.1%, no more than 0.5%, or no more than 0.04% of silicon (e.g., 0-0.04% max, Si).
  • the alloy may be entirely free of silicon.
  • the alloy may be substantially or entirely free of phosphorous and/or sulfur, as quantified above (e.g., no more than 0.04%, or no more than 0.04% max by weight of each).
  • phosphorus may be at 0% to 0.04% max
  • sulfur if present, may be at 0% to 0.03% max.
  • Iron may be present, or absent, in small amounts (e.g., 0% to 3% max Fe).
  • the radiopaque stent of the present disclosure overcomes limitations of other stents, e.g., particularly L-605 stents, which exhibit less than ideal radiopacity, without increasing tungsten content, which can result in solubility problems, as tungsten normally separates into a second phase in Co-Cr at concentrations slightly greater than 15% by weight.
  • the present methods disclose how to ensure that the stent can be formed from a homogenous material (no coatings, no varying metallic layers, no radiopaque markers or the like), in which the alloy exhibits a substantially homogenous single-phase microstructure, even though precipitates normally form within such a composition, which precipitates are not resolved through conventional heat treatments.
  • the presently described treatments are surprisingly capable of resolving such problems.
  • Such a stent imparts a more visible image when absorbing x-rays during fluoroscopy as compared to a dimensionally similar L-605 stent. With this more visible image, the entire stent is better observed by the practitioner placing the stent. The image observed by the practitioner is not "washed out” due to excessive brightness and is not too dim. Because of the improved image contrast, the stent is accurately positioned and manipulated within a lumen of a patient, with a radiopacity such that stent expansion during and after deployment may be assessed accurately by the practitioner. An additional advantage to the increased radiopacity is the visualization of the stent and the underlying vessel during follow-up examinations by the practitioner.
  • the entire stent is radiopaque, the diameter and length of the stent are readily discerned by the practitioner. Also, because the stent itself is made of the radiopaque alloy, the stent does not have problems associated with radiopaque coatings or varying metallic layers (e.g., no core/shell structure), such as cracking or separation or corrosion at interfaces inherent in such configurations. Also, because the entire stent is radiopaque, the stent does not require extra markers with their attendant issues.
  • a stent where at least a portion of the stent (e.g., the stent body, or a core, or a shell thereof) is formed from the alloy and processes described herein, and another portion of the stent (e.g., the other of the core or shell, or markers) are formed from a different material and/or process.
  • the stent e.g., the stent body, or a core, or a shell thereof
  • another portion of the stent e.g., the other of the core or shell, or markers
  • a stent constructed of a Co-Cr-Ni-W-Pt alloy as contemplated herein can be made thinner than one of stainless steel without sacrificing fluoroscopic visibility.
  • the low profile of the Co-Cr-Ni-W-Pt stent renders the stent more deliverable with greater flexibility. While platinum is an exemplary material for inclusion in the present alloy in order to increase radiopacity, it will be appreciated that other radiopacifying elements with a radiopacity greater than that provided by cobalt may alternatively or additionally be used.
  • any of various platinum group metals, precious metals, or refractory metals described in applicant’s U.S. Patent Nos. 9,566,147; 10,441,445 and 11,298,251, as well as U.S. Application Nos. 13/298,070; 61/414,566; 62/914,806; 17/068,526 and 17/562,592 may also benefit from the processing steps described herein, particularly where such alloy may include Co, Cr, and W (e.g., Co, Cr, Ni, W, and one or more selected radiopacifying elements).
  • Co, Cr, and W e.g., Co, Cr, Ni, W, and one or more selected radiopacifying elements
  • a Co-Cr-Ni-W-Pt alloy that includes, e.g., 20-25% platinum by weight in a substantially homogenous (single-phase) composition results in improved radiopacity of the low profile stent of the present disclosure over prior art cobalt chromium alloys, and increases deliverability of the stent and may offer significant performance advantages regarding decreasing the fluid mechanical disturbances of blood flow. Improved radiopacity assists the practitioner in placing the device precisely. Inflation or other deployment of the stent is better monitored because the stent is better visible to the practitioner. This visibility reduces the incidence and probability of an under-deployed stent.
  • in-stent restenosis is monitored as the stent and an injected contrast agent are able to be imaged simultaneously.
  • the stent of the present disclosure does not produce an image which is too bright, thereby obscuring imaging of the underlying vessel morphology.
  • L-605 cobalt chromium alloys containing up to 15% by weight tungsten, such as L-605 have been used in many applications, these alloys have insufficient radiopacity.
  • the composition of L-605 is as follows. Values may vary somewhat (e.g., ⁇ 1 percentage point).
  • L-605 is reported to have a melting range of 1602 to 1683K (e.g., 1329°C to
  • This alloy in annealed bar form has a minimum ultimate tensile strength of 125 ksi, a minimum yield strength of 45 ksi and a minimum total elongation of 30%.
  • the contemplated alloys may have similar tensile strength, yield strength, and elongation properties, as such properties are desirable. That said, the relative radi opacity of L-605 is lacking, e.g., being only 3.6 barnes/cc.
  • the tube draw process involves several stages of draw through dies that reduce the tube diameter, as well as cleaning and annealing heat treatments.
  • the annealing heat treatment re-creates the crystalline structure of the alloy and softens the material in preparation for the next stage of tube draw.
  • the “P-605” alloy differs in composition from standard L-605, the same settings for normalization, tube draw, and annealing heat treatment used for processing L-605 are not applicable. In order to develop these processes and monitor the condition of the new P-605 alloy, metallographic analysis was conducted regularly during the testing process described herein.
  • FIG. 1 shows an example of the problematic microstructure detected, in the form of unacceptably high levels of precipitates present in the alloy, particularly at the grain boundaries, as shown. Conventional heat treatments were not able to resolve such precipitates.
  • the alloy structure has an irregular appearance.
  • the darker lines are grain boundaries were the acid used during etching has preferentially attacked material at the grain boundaries. This appears similar to voids or depressions in the material, although this is not the case in the actual alloy and such grain boundary appearance is not unusual after etching.
  • the real problem seen in FIG. 1 is the presence of the lighter colored particles. These precipitate formations are not part of the normal desired alloy structure, but are made up of significantly harder, non-ductile particles, having a composition that differs from the much softer ductile structure of the desired homogenous alloy.
  • Such particles are unacceptable in materials for cardiovascular stent applications, for multiple reasons.
  • stents need to be ductile to facilitate compression onto the balloon, deployment, and to allow for minor distortion that occurs during heartbeat compression of the artery.
  • the observed precipitate particles result in an overall structure that does not have a homogeneous crystalline structure.
  • Experience by applicant has shown that these particles are hard ceramic-like crystalline precipitates that are not ductile, and not capable of mechanical distortion like the normal alloy structure.
  • Typical cobalt chrome alloy manufacture is known to sometimes result in precipitate particles that appear similar to those shown in FIG. 1.
  • Precipitate formation in solid metals during heat treatment are described by Temperature, Time, Transition (TTT) graphs, such as shown in FIG. 2, which shows an exemplary TTT chart for L-605 alloy (Julien Favre, Damien Fabregue, Eric Maire, Akihiko Chiba. Grain growth and static recrystallization kinetics in Co-20Cr-15W-10Ni (L-605) cobalt-base superalloy.
  • FIG. 2 illustrates how precipitate formations are formed in solid metals.
  • the Y axis shows temperature and the X axis shows time.
  • the multiple illustrated curves refer to different stoichiometric forms of precipitates, and the conditions (time and temperature) under which such precipitates form.
  • Many of the precipitates are various forms of ceramic-like intermetallic compounds formed from cobalt and tungsten, while others are metal carbides.
  • the “M” in FIG. 2 designates that any of various metals that are present may form such a carbide precipitate.
  • TTT diagrams show formation conditions in ideal conditions, and real-world variability such as volume of metal, surface area ratios, and slight variations in composition may influence actual results. As such, TTT diagrams can be a guide to conditions that may result in precipitate formation, rather than an exact representation of what is occurring under real manufacturing conditions.
  • TTT diagram One insight that can be gleaned from a TTT diagram is determination at what temperature no precipitates should form, even if the alloy is held at such temperature for an extended period.
  • the TTT diagram shown in FIG. 2 indicates this condition should be prevalent above 1200°C.
  • Another key learning from the TTT of FIG. 2 is that at such elevated temperatures, any precipitates that may be present would be expected to dissolve back into the alloy structure, if held at such temperature for sufficient time for equilibrium to be reached.
  • conventional thinking is that the formation of precipitates in the alloy structure should be resolved by heat treating to this temperature range, followed by rapid cooling of the alloy to prevent reformation of precipitates.
  • Tungsten has the highest meting temperature of any metal, at over 3400°C. Its atoms are large compared to other elements in L-605 so it is expected that dissipation of precipitates containing tungsten should require high temperature and long dwell times at such elevated temperature to cause the precipitates to dissolve.
  • the volume and surface area of the tube being treated may also be a relevant factor. For example, the relatively low cross-sectional volume and large surface area to volume ratio of such tubing allows for rapid heating and cooling of the alloy.
  • the conventional path to resolve tungsten carbide precipitates in an L-605 alloy would be to monitor the structure over subsequent annealing stages as the precipitates gradually dissipate. At a finished tube wall thickness of 100 microns such precipitates should be dissipated during a single annealing cycle.
  • composition and phases in metallic alloys are highly complex - alloy phase diagrams and studies of L-605 Co-Cr are available but references for the composition of P-605 are not available;
  • the tungsten rich particulate formations may either not be a precipitate or could be a formation that once generated, subsequent heat treatment cannot resolve;
  • phase diagram for Co-Cr shows several atomic crystalline structures that exist according to temperature and processing conditions, as shown in FIG. 3.
  • the Co-Cr phase diagram of FIG. 3 illustrates the crystal phases that exist with increasing proportion of chromium in a pure cobalt-chromium alloy.
  • L-605 contains 18% to 22% chromium, and the important phase structure needed for flexibility of stent materials is shown as aCo in the phase diagram of FIG. 3.
  • FIG. 3 the utility of FIG.
  • L-605 and P-605 alloys contain several other alloying elements such as nickel, tungsten, manganese, (and platinum in the case of P-605) in addition to chromium.
  • L-605 nor P-605 alloys are simple binary alloys, such as that of FIG. 3.
  • C03W an intermetallic compound
  • EDS analysis of the precipitates showed high tungsten content, it also showed the presence of trace cobalt.
  • Particular features of this intermetallic compound include very high stability, and a tendency for this material to gradually form over time. It was observed that the previous attempts to dissipate the tungsten rich compound focused on high temperature and extended time believing that this was needed for tungsten to migrate, and cause the precipitate to dissolve. It was further theorized that these conditions may actually promote formation and stability of a C03W intermetallic compound, so that the extended time approach would not resolve the issue. Even though the data shown in FIG. 2 shows that C03W does not form at temperatures over about 800°C in L-605, the different observed results may be due to the alloy being P-605, or other unpredictable factors.
  • FIG. 4 shows the resulting microstructure of the same material shown in FIG. 4, after treatment at 1250°C for 30 minutes.
  • the structure of the alloy has completely changed and the degree of intermetallic compound has been dramatically reduced, disappearing almost completely.
  • EDS analysis showed this to be a tungsten rich particle similar to the originally detected particles.
  • the size of the detected particle (labeled “spectrum 4” in FIG. 5) was around 3 pm or less. This result eliminated the theory that tungsten solubility was the cause of the observed precipitation. It is also apparent from FIG. 5 that grain boundary appearance has also dramatically changed, showing a much more uniform composition within the alloy.
  • the rapid quench may be performed within a period of time of less than 5 minutes, less than 3 minutes, less than 2 minutes, or less than 1 minute.
  • the rapid quench may be performed by immersing the alloy in water.
  • the alloy comprises cobalt, in an amount of from 20% to 40% by weight.
  • the alloy comprises chromium in an amount of about 20% by weight.
  • the alloy comprises nickel in an amount of about 10% by weight.
  • the alloy is substantially or entirely free of molybdenum.
  • the alloy is substantially or entirely free of carbon.
  • the alloy comprises no more than 1% by weight of each of silicon, phosphorus, and/or sulfur.
  • the alloy comprises manganese in an amount of up to 5% by weight.
  • the alloy comprises both manganese and iron in an amount of up to about 3% each, by weight.
  • the sum of cobalt and platinum comprises from about 48% to about 60%, or 50% to 57% (e.g., about 55%) by weight of the alloy.
  • the alloy comprises: about 20-37% cobalt; about 20-30% platinum; about 19-21% chromium; about 14-16% tungsten; about 9-11% nickel; and about 1-2% manganese.
  • the alloy further comprises one or more trace elements as follows:
  • the precipitate inclusions comprise tungsten (e.g., a majority tungsten, e.g., where cobalt may also be present). In an embodiment, the precipitate inclusions comprise Co3W.
  • the alloy may be heated to about 1250°C for a period of time that is less than 60 minutes, less than 50 minutes, no more than 45 minutes, no more than 40 minutes, such as about 30 minutes.
  • the period of time may be at least 10 minutes, at least 15 minutes, or at least 20 minutes, such as 20-40 minutes.
  • the temperature to which such heating may occur may be 1275°C or less, at least 1200°C, at least 1225°C, such as 1230°C to 1270°C, 1240°C to 1260°C, such as about 1250°C.
  • the alloy is rapidly cooled from the above noted temperature, to 600°C or less, within less than 1 minute. Such may be achieved within a water quench bath (e.g., immersing the alloy after treatment at the above temperature and hold time). Rapid cooling of the alloy may aid in maintaining the desired substantially homogenous structure seen in FIG. 5.
  • nickel suppresses cobalt’s allotropic transformation from a face-centered-cubic (“FCC”) crystal structure (where it is stable at high temperatures) to a hexagonal-close-packed (“HCP”) structure (where it is stable at low temperatures). In pure cobalt, this transformation naturally occurs at around 422°C.
  • FCC face-centered-cubic
  • HCP hexagonal-close-packed
  • the addition of nickel significantly reduces cobalt’s transformation temperature, thereby favoring the FCC structure, which in general, is a more ductile and more creep-resistant crystal structure than HCP.
  • the rapid cooling of the alloy solution serves to trap the cobalt in the favored FCC structure, minimizing or eliminating formation of any substantial amounts of HCP structure.
  • the temperatures and cooling times of the processing described herein may be directly focused on the resolution of tungsten rich precipitates that may otherwise form, to achieve a substantially homogenous, singlephase, FCC microstructure, rather than any considerations related to potential carbide formation, or other purposes.
  • iron and/or manganese may be present, they each may represent no more than 3%, or no more than 2% (e.g., 1.5% by weight) of the alloy.
  • the alloy may also be free, or substantially free of other elements of the periodic table not specifically listed in exemplary alloys described herein.
  • the resulting alloys are advantageously stable and may be compatible with additional heat treatments, such as age hardening, without disturbing the desired substantially homogenous microstructure shown in FIG. 5.
  • subsequent age hardening treatments may include heating the alloy to 600 to 1000°C, 600 to 800°C, or 600 to 675°C for at least about 1 hour, at least about 4 hours, at least about 8 hours, at least about 16 hours, from 1 hour to 256 hours, or from 1 hour to 16 hours.
  • Aging for the described time periods at the described temperatures may aid ensuring that any C03W particulates still present exhibit very small grain or particle sizes.
  • the austenitic stabilization of the material advantageously prevents significant formation of HCP structure.
  • the age hardening can be configured to impart a particular yield strength to the material, according to the intended use, without affecting radiopacity.
  • any secondary phase is limited to no more than 10% volume fraction, no more than 5% volume fraction, no more than 3% volume fraction, no more than 2% volume fraction, or no more than 1% volume fraction.
  • Any present second phase further may be well dispersed, e.g., having a maximum or even average particle size of no more than 5 pm, such as from 0.5 pm to 5 pm.
  • An example of such a substantially homogenous structure is shown in FIG. 5.
  • the alloy of the current disclosure may have a yield strength of at least 45 ksi (310 MPa).
  • the radiopaque stent of the present disclosure is fabricated from a single tube of Co-Cr-Ni-W-Pt alloy subjected to chemical etching, laser machining, conventional machining, electronic discharge machining (EDM), ion milling, slurry jet, or electron beam treatment or combinations of these treatments.
  • the stent is fabricated from wire elements of Co-Cr-Ni-W-Pt alloy that are welded together.
  • the stent is fabricated from flat stock and is patterned, then rolled and welded.
  • the stent is fabricated from near-net shape processing such as metal injection molding.
  • the alloy may consist essentially of Co, Cr, Ni, W, and Pt, where any additional elements that may be present, may be present at less than 2% by weight (e.g., particularly in the case of Mn and/or Fe), less than 1%, or less than 0.5%, or less than 0.25% (e.g., particularly in the case of Si, P, and/or S), if at all.
  • the radiopaque stent of the present disclosure may be fabricated according to any number of configurations.
  • Non-limiting exemplary configurations include a solid cylinder, illustrated at 70 in FIG. 6, a coiled stent illustrated at 90 in FIG. 7, a ratcheting stent 100, illustrated in FIG. 8, a stent embodiment 80 with a backbone 81, illustrated in FIG. 9 or a stent embodiment 82 with a staggered backbone, illustrated in FIG. 10. Additional configurations are shown in FIGs. 11-12.
  • the entirety of the stent body may be formed from the radiopaque Co-Cr alloy described herein (e.g., without various metallic layers, markers, or the like).
  • Radiopaque stent design embodiment is a high precision patterned cylindrical device.
  • An example of such is illustrated generally at 10 in FIG. 13.
  • the stent 10 typically comprises a plurality of radially expanded cylindrical elements 12 disposed generally coaxially and interconnected by elements 13 disposed between adjacent cylindrical elements.
  • the stent 10 is expanded by a delivery catheter 11.
  • the delivery catheter 11 has an expandable portion or a balloon 14 for expanding of the stent 10 within an artery 15.
  • the delivery catheter 11 onto which the stent 10 is mounted is similar to a conventional balloon dilation catheter used for angioplasty procedures.
  • the artery 15, as shown in FIG. 13, has a dissected lining 16 which has occluded a portion of the arterial passageway.
  • Each radially expandable cylindrical element 12 of the radiopaque stent 10 is independently expandable. Therefore, the balloon 14 may be provided with an inflated shape other than cylindrical, e.g., tapered, to facilitate implantation of the stent 10 in a variety of body lumen shapes.
  • the delivery of the radiopaque stent 10 is accomplished by mounting the stent 10 onto the inflatable balloon 14 on the distal extremity of the delivery catheter 11. The catheter- stent assembly is introduced within the patient's vasculature using conventional techniques through a guiding catheter which is not shown.
  • a guidewire 18 is disposed across the damaged arterial section and then the catheter- stent assembly is advanced over a guidewire 18 within the artery 15 until the stent 10 is directly under detached lining 16 of the damaged arterial section.
  • the balloon 14 of the catheter is expanded, expanding the stent 10 against the artery 15, which is illustrated in FIG. 14.
  • the artery 15 is preferably expanded slightly by the expansion of the stent 10 to seat or otherwise fix the stent 10 to prevent movement.
  • the artery may have to be expanded considerably in order to facilitate passage of blood or other fluid therethrough. This expansion is easily observable by the interventionalist with the radiopaque stent of the present disclosure. While balloon expandable stents are described, it will be appreciated that the alloys and configurations described herein may, in at least some embodiments, be self-expanding.
  • the stent 10 serves to hold open the artery 15 after the catheter 11 is withdrawn, as illustrated in FIG. 15. Due to the formation of the stent 10 from the elongated tubular member, the undulating component of the cylindrical elements of the stent 10 is relatively flat in transverse cross section so that when the stent is expanded, the cylindrical elements are pressed into the wall of the artery 15 and as a result do not interfere with the blood flow through the artery 15.
  • the cylindrical elements 12 of the stent 10 which are pressed into the wall of the artery 15 are eventually covered with endothelial cell growth which further minimizes blood flow interference.
  • the undulating pattern of the cylindrical sections 12 provides good characteristics to prevent stent movement within the artery.
  • the closely spaced cylindrical elements at regular intervals provide uniform support for the wall of the artery 15, and consequently are well adapted to tack up and hold in place small flaps or dissections in the wall of the artery 15 as illustrated in FIG. 14 and FIG. 15.
  • the undulating pattern of the radiopaque stent is readily discernable to the interventionalist performing the procedure.
  • FIG. 11 is an enlarged perspective view of the stent 10 shown in FIG. 13 with one end of the stent shown in an exploded view to illustrate in greater detail the placement of interconnected elements 13 between adjacent radially expandable cylindrical elements 12.
  • Each pair of interconnecting elements 13 on one side of the cylindrical element 12 are positioned to achieve maximum flexibility for the stent 10.
  • the stent 10 has three interconnecting elements 13 between adjacent radially expandable cylindrical elements 12 which are 120 degrees apart.
  • Each pair of interconnecting elements 13 on one side of a cylindrical element 12 are offset radially 60 degrees from the pair on the other side of the cylindrical element.
  • the alternation of the interconnecting elements results in a stent which is longitudinally flexible in essentially all directions.
  • interconnecting elements are possible. However, as previously mentioned, all of the interconnecting elements of an individual stent are secured to either the peaks or valleys of the undulating structural elements in order to prevent shortening of the stent during the expansion thereof.
  • the number of undulations may be varied to accommodate placement of interconnecting elements 13, e.g., at the peaks of the undulations or along the sides of the undulations as shown in FIG. 12.
  • cylindrical elements 12 are in the form of a serpentine pattern 30. As previously mentioned, each cylindrical element 12 is connected by interconnecting elements 13.
  • Serpentine pattern 30 is made up of a plurality of U-shaped members 31, W-shaped members 32 and Y-shaped members 33, each having a different radius so that expansion forces are more evenly distributed over the various embodiments.
  • the illustrative stent 10 and other stent structures can be made using several techniques, including laser machining.
  • One method of making the radiopaque stent is to cut a thin walled tubular member made of the radiopaque Co-Cr-Ni-W-Pt alloy described herein, to remove portions of the tubing in a desired pattern for the stent, leaving relatively untouched the portions of the radiopaque Co-Cr-Ni-W-Pt alloy tubing which are to form the stent.
  • the tubing is cut in a desired pattern using a machine-controlled laser as illustrated schematically in FIG. 16.
  • the stent has an outer diameter on the order of about 0.04 to 0.10 inches in the unexpanded condition, approximately the same outer diameter of the tubing from which it is made, and may be expanded to an outer diameter in a range of about 1 to 15 millimeters. Stents for peripheral and other larger vessels may be constructed from larger diameter tubing. The strut thickness in a radial direction is in a range of 0.001 to 0.01 inches.
  • the tubing 21 is put in a rotatable collet fixture 22, of a machine controlled apparatus 23 for positioning the tubing 21 relative to a laser 24.
  • the tubing 21 is rotated and moved longitudinally relative to the laser 24 which is also machine controlled.
  • the laser selectively removes the material from the tubing by ablation and a pattern is cut into the tube.
  • the tube is therefore cut into the discrete pattern of the finished stent.
  • the process for cutting a pattern for the stent into the tubing may be automated except for loading and unloading the length of tubing. Referring again to FIG. 16, it may be done, for example, using a CNC opposing collet fixture 22 for axial rotation of the length of tubing. In conjunction with a CNC X-Y table 25 to move the length of tubing axially relatively to a machine-controlled laser as described. The entire space between collets is patterned using a laser setup of the foregoing example. The program for control of the apparatus is dependent on the particular configuration used.
  • the tubes are made of a Co-Cr-Ni-W-Pt alloy as described herein that includes significant platinum content (e.g., 20-30% platinum by weight), while maintaining primarily single-phase characteristics within the alloy.
  • the tubes have an outside diameter of 0.04 inches to 0.10 inches and a wall thickness of 0.001 inches to 0.010 inches.
  • the tubes are fixed under a laser and are positioned using a CNC to generate a very intricate and precise pattern. Due to the thin wall and the small geometry of the stent pattern, it is necessary to have very precise control of the laser, its power level, the focus spot size and the precise positioning of the laser cutting path.
  • the system of the present disclosure using such lasers and their available parameter adjustments, makes it possible to cut using a narrow beam which minimizes the heat input into the material.
  • the positioning of the cylindrical radiopaque Co-Cr-Ni-W-Pt alloy structure benefits from use of precision CNC equipment.
  • a rotary mechanism can be provided that allows the computer program to be written as if the pattern were being cut from a flat sheet. This allows both circular and linear interpolation to be used in programming.
  • the optical system which expands the original laser beam delivers the beam through a viewing head and focuses the beam onto the surface of the tube, may include a coaxial gas jet and nozzle that helps remove debris from the cut face and cools the region where the beam interacts with the material as the beam cuts and vaporizes the metal. Such is also advantageous to block the beam as it cuts the top surface of the tube and prevent the beam, along with the molten metal and debris from the cut, from impinging on the opposite surface of the tube.
  • the optical delivery system can include a beam expander to increase the laser beam diameter, a circular polarizer, typically in the form of a quarter wave plate, to eliminate polarization effects in metal cutting, provisions for a spatial filter, a binocular viewing head and focusing lens, and a coaxial gas jet that provides for the introduction of a gas stream which surrounds the focus beam and is directed along the beam axes.
  • a beam expander to increase the laser beam diameter
  • a circular polarizer typically in the form of a quarter wave plate, to eliminate polarization effects in metal cutting
  • provisions for a spatial filter, a binocular viewing head and focusing lens provisions for a spatial filter, a binocular viewing head and focusing lens
  • a coaxial gas jet that provides for the introduction of a gas stream which surrounds the focus beam and is directed along the beam axes.
  • the cutting process typically uses an assist gas with the laser beam, resulting in a narrow cut area and minimal molten slag along the cut.
  • the cut tube can be soaked in an appropriate solution of mineral acids. Before it is soaked, the tube may be ultrasonically cleaned in a mineral acid solution after cutting.
  • Direct laser cutting produces edges which are essentially perpendicular to the axes of the laser cutting beam in contrast with chemical etching and the like which may produce patterned edges which are angled.
  • the laser cutting process essentially provides stent cross sections from cut-to-cut which are square or rectangular.
  • cylindrical elements 12 are comprised of struts 30 which have generally rectangular cross sections 32 wherein the stent is laser cut from a tubular member.
  • the struts have generally perpendicular edges 31 formed by the laser cut.
  • the resulting stent structure provides superior performance. That said, it is possible to form stents according to the present disclosure using techniques other than laser cutting, while still providing benefits associated with the enhanced radiopacity, primarily single-phase alloy while substantially eliminating the presence of secondary phase tungsten rich precipitates, as described herein.
  • the radiopaque Co-Cr-Ni-W-Pt alloy stent of the present disclosure is fabricated of radiopaque Co-Cr-Ni-W-Pt alloy wire elements.
  • the stent is made of a radiopaque Co-Cr-Ni-W-Pt alloy flat stock.
  • the stent is made of radiopaque Co-Cr-Ni-W-Pt alloy materials using near-net shape processing such as metal injection molding.
  • the stent When expanded, the stent may cover about 10-45% of an arterial wall surface area.
  • the radiopaque Co-Cr-Ni-W-Pt alloy stent of the present disclosure can withstand at least about 30% tensile deformation before failure.
  • the term “between” includes any referenced endpoints. For example, “between 2 and 10” includes both 2 and 10.
  • any of the disclosed alloys and processes may also be used in the manufacture of other devices, such as medical devices, including, but not limited to guide wires, guide wire tip coils, balloon markers, balloon expandable valves, or other structures associated with catheter use, and other implantable structures in which improved radiopacity would be desirable.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Materials Engineering (AREA)
  • Mechanical Engineering (AREA)
  • Metallurgy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Materials For Medical Uses (AREA)
  • Thermal Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)

Abstract

L'invention concerne des structures implantables radio-opaques (par ex., des endoprothèses) formées d'alliages à base de cobalt qui comprennent du cobalt, du chrome, du tungstène, du nickel et du platine ou un autre métal ayant un numéro atomique supérieur à celui du cobalt ou une densité supérieure à celle du cobalt pour une radio-opacité accrue. En particulier, des procédés sont décrits pour éliminer des inclusions de précipité (par ex., des précipités riches en tungstène) qui autrement rendent l'alliage inapproprié pour une utilisation dans la formation d'une endoprothèse ou structure implantable similaire. L'alliage ayant de telles inclusions de précipité peut être traité thermiquement au sein d'une plage de température étroite d'environ 1250 °C (par ex., de 1225 °C à 1275 °C) pendant une durée dans une plage étroite d'environ 30 minutes (par ex., de 20 à 40 minutes), pour éliminer de telles inclusions de précipité. Des températures plus élevées et/ou des temps de traitement plus longs, de manière surprenante, ne résolvent pas les inclusions de précipité, mais un traitement à environ 1250 °C pendant environ 30 minutes élimine sensiblement les précipités, résultant en une structure sensiblement homogène appropriée pour une utilisation comme une endoprothèse.
PCT/US2023/023963 2022-06-08 2023-05-31 Traitement d'alliages cobalt-tungstène WO2023239573A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263350106P 2022-06-08 2022-06-08
US63/350,106 2022-06-08
US18/324,749 2023-05-26
US18/324,749 US20230399725A1 (en) 2022-06-08 2023-05-26 Processing of cobalt-tungsten alloys

Publications (1)

Publication Number Publication Date
WO2023239573A1 true WO2023239573A1 (fr) 2023-12-14

Family

ID=87036263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/023963 WO2023239573A1 (fr) 2022-06-08 2023-05-31 Traitement d'alliages cobalt-tungstène

Country Status (1)

Country Link
WO (1) WO2023239573A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130096669A1 (en) * 2011-10-12 2013-04-18 Abbott Cardiovascular Systems, Inc. Partially annealed stent
US9566147B2 (en) 2010-11-17 2017-02-14 Abbott Cardiovascular Systems, Inc. Radiopaque intraluminal stents comprising cobalt-based alloys containing one or more platinum group metals, refractory metals, or combinations thereof
US20210106729A1 (en) * 2019-10-14 2021-04-15 Abbott Cardiovascular Systems, Inc. Methods for manufacturing radiopaque intraluminal stents comprising cobalt-based alloys with supersaturated tungsten content
US11298251B2 (en) 2010-11-17 2022-04-12 Abbott Cardiovascular Systems, Inc. Radiopaque intraluminal stents comprising cobalt-based alloys with primarily single-phase supersaturated tungsten content

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9566147B2 (en) 2010-11-17 2017-02-14 Abbott Cardiovascular Systems, Inc. Radiopaque intraluminal stents comprising cobalt-based alloys containing one or more platinum group metals, refractory metals, or combinations thereof
US20170296365A1 (en) * 2010-11-17 2017-10-19 Abbott Cardiovascular Systems, Inc. Radiopaque intraluminal stents comprising cobalt-based alloys containing one or more platinum group metals, refractory metals, or combinations thereof
US10441445B2 (en) 2010-11-17 2019-10-15 Abbott Cardiovascular Systems, Inc. Radiopaque intraluminal stents comprising cobalt-based alloys containing one or more platinum group metals, refractory metals, or combinations thereof
US11298251B2 (en) 2010-11-17 2022-04-12 Abbott Cardiovascular Systems, Inc. Radiopaque intraluminal stents comprising cobalt-based alloys with primarily single-phase supersaturated tungsten content
US20130096669A1 (en) * 2011-10-12 2013-04-18 Abbott Cardiovascular Systems, Inc. Partially annealed stent
US20210106729A1 (en) * 2019-10-14 2021-04-15 Abbott Cardiovascular Systems, Inc. Methods for manufacturing radiopaque intraluminal stents comprising cobalt-based alloys with supersaturated tungsten content

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JULIEN FAVREDAMIEN FABREGUEERIC MAIREAKIHIKO CHIBA: "Grain growth and static recrystallization kinetics in Co-20Cr-15W-10Ni (L-605) cobalt-base superalloy", PHILOSOPHICAL MAGAZINE, vol. 94, no. 18

Similar Documents

Publication Publication Date Title
US8852264B2 (en) Radiopaque intraluminal stent
Poncin et al. Stent tubing: understanding the desired attributes
US8137614B2 (en) Medical devices and method for making the same
US7780798B2 (en) Medical devices including hardened alloys
US8500787B2 (en) Radiopaque markers and medical devices comprising binary alloys of titanium
US9272376B2 (en) Fatigue-resistant nickel-titanium alloys and medical devices using same
US8500786B2 (en) Radiopaque markers comprising binary alloys of titanium
EP1604691B1 (fr) Alliages biocompatibles pour articles médicaux implantables
WO2012008579A1 (fr) Stent à module d'élasticité élevé et son procédé de production
EP1604692B1 (fr) Alliage à base de cobalt, nickel et chrome pour des dispositifs médicaux implantables
US20130096669A1 (en) Partially annealed stent
US20210106729A1 (en) Methods for manufacturing radiopaque intraluminal stents comprising cobalt-based alloys with supersaturated tungsten content
US20230399725A1 (en) Processing of cobalt-tungsten alloys
WO2023239573A1 (fr) Traitement d'alliages cobalt-tungstène
EP1614435A1 (fr) Alliage à imagerie à résonance magnétique pour des dispositifs médicaux implantables
US20240229289A1 (en) Method of mass removal and electropolishing of stent alloys containing noble elements
WO2024151340A1 (fr) Procédé d'élimination de masse et d'électropolissage d'alliages d'endoprothèse contenant des éléments nobles
JP2014036817A (ja) 機能性金属チューブ部材およびその製造方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23734818

Country of ref document: EP

Kind code of ref document: A1